Christina Muzny: Secnidazole for the Treatment of Trichomoniasis and Bacterial Vaginosis
It was a great pleasure to meet with Dr Christina Muzny (University of Alabama at Birmingham, Birmingham, AL, USA) to discuss the findings from the recent Phase III clinical study that has led to the approval of secnidazole for the treatment of trichomoniasis and bacterial vaginosis.
Questions:
- What are the unmet needs in the treatment of trichomoniasis and bacterial vaginosis? (0:18)
- What is the mechanism of action of secnidazole? (2:49)
- Could you tell us a little about the Phase III clinical study that has led to the approval of secnidazole? (3:55)
- What were the efficacy and safety findings of the study? (5:17)
- What will be the impact of this approval on clinical practice? (6:18)
Disclosures: Christina Muzny has received research grants to my UAB from, NIH, Lupin, Gilead, Abbott; is on the Speaker Board for Cepheid; is on Scientific Advisory Boards for PhagoMed, Roche, Abbott; receives speaker honoraria -from Cepheid, Roche, BD, Abbott; and is involved in the development of educational presentations for Jesperson & Associates.
Support: Interview and filming supported by Touch Medical Media. Interview conducted by Katey Gabrysch.
